Sir,
Merkel cell carcinoma (MCC) also called as cutaneous neuroendocrine carcinoma generally presents as rapidly growing solitary firm red to violaceous nodule with a smooth shiny surface with the involvement of photo exposed areas of face and neck in 50% cases, extremities in 40% of cases, and trunk and mucosa in less than 10% of cases. Ulceration is rarely observed in advanced cases. Risk factors for MCC include advanced age with mean age of diagnosis at 70 years, UV radiation, immunosuppressed states like organ transplant recipients, HIV infection, or malignancies. Merkel cell polyoma virus (MCPyV) has been recently postulated in the pathogenesis of MCC with MCPyV found to be clonally integrated in the genome of MCC tumor cells in 80% cases. It is an aggressive tumor with poor prognosis, with a 5-year mortality of 40% and shows a tendency for local recurrence, lymph node involvement, and distant metastasis. MCC is a very rare skin cancer with an incidence of 0.44/1,00,000 in US and has been rarely reported in Indian population. We report a case of MCC in an elderly male with two unusual clinical features—arising on photo protected site on lower back as an ulcerated growth mimicking squamous cell carcinoma and developing de novo without any underlying immunosuppression.

An 85-year-old male patient presented with asymptomatic gradually progressive growth over the lower back of 4 years duration, rapidly progressing since 4 months with ulceration. There was no history of weight loss or any other systemic complaints. Before presenting to our center patient had consulted a few other clinicians; however, the lesion was not subjected to histopathology examination. Examination revealed the involvement of left lower back in the form of solitary fungating growth with ulceration measuring 5 cm × 4 cm × 3.5 cm. Few sub-centimetric, discrete, hyperpigmented to erythematous satellite plaques were present in the vicinity of growth. Patient was investigated with the differentials of squamous cell carcinoma, amelanotic melanoma, cutaneous lymphoma, and chronic granulomatous diseases like cutaneous leishmaniasis. Hematological and biochemical investigations were normal. Enzyme-linked immunosorbent assay for HIV was negative.

Skin biopsy for histopathology showed ulcerated tissue infiltrated by nests and trabeculae of round blue cells on low power, with high nucleocytoplasmic ratio, scant cytoplasm, dispersed powdery chromatin, inconspicuous nuclei, and brisk mitotic activity seen on higher power. Immunohistochemistry was done to differentiate small round blue cell tumors of skin which showed positive CK20, synaptophysin, chromogranin, CD56, EMA, and CD117 along with negative p40, CK7, vimentin, LCA, CD3, CD20, BERP4, and CD138. MIB1 labelling index was high both in tumor cells and underlying squamous epithelium. Lympho-vascular invasion was seen at tumor margins. Final diagnosis was given as MCC with carcinoma in situ changes in lining squamous epithelium. Diagnosis of in situ carcinoma changes in the underlying squamous epithelium was made on the basis of histopathological features of high-grade dysplasia along with findings of high MIB-1 index with no unequivocal invasion by dysplastic squamous cells.

Positron Emission Tomography-Computed Tomography (PET-CT) scan for tumor spread did not reveal any distant metastasis. Enzyme-linked immunosorbent assay for polyoma virus (MCPyV) was negative. Lympho‑vascular invasion was seen at tumor margins. Final diagnosis was given as MCC with carcinoma in situ changes in lining squamous epithelium. Diagnosis of in situ carcinoma changes in the underlying squamous epithelium was made on the basis of histopathological features of high-grade dysplasia along with findings of high MIB-1 index with no unequivocal invasion by dysplastic squamous cells.

How to cite this article: Singh GK, Sinha A, Mishra FS, Jain A, Beniwal NS. Ulcerative variant of Merkel cell carcinoma in an immunocompetent individual: An unusual presentation. Indian Dermatol Online J 2021;12:156-8.

Received: 26-Mar-2020. Revised: 23-Jul-2020. Accepted: 12-Sep-2020. Published: 16-Jan-2021.
and metastasis revealed FDG avid exophytic lesion in posterior abdominal wall, FDG avid nodular lesions in abdomen abutting left internal oblique muscle, and subcutaneous nodular lesions in Rt inguinal region suggesting metastasis [Figure 4a-d]. Patient was managed with wide local excision of tumor with 1 cm margin. Gross section of the excised specimen revealed an encapsulated nodular ulcerative tumor measuring 5 cm × 4 cm × 3.5 cm. Cut surface was gray pink, soft with areas of punctate hemorrhages and necrosis. Patient was started on radiotherapy and was offered chemotherapy which he declined, and subsequently succumbed to his illness within 2 months of diagnosis of the disease.

The first description of MCC was given by Toker who called it Trabecular carcinoma of the skin.[5] MCC has a varied clinical presentation although rapid growth of an asymptomatic red violaceous papule or nodule is classically noted. In the absence of underlying immunodeficiency syndromes and diseases, age-related decline of immune function and cumulative doses of UV rays are implicated as risk factors.[6] In our reported case, advanced age of 85 years was a contributing factor, but the photo protected site of lower back is a rare site for origin of MCC.

Clinical differentials of squamous cell carcinoma, cutaneous lymphoma, and amelanotic melanoma were given initially owing to the atypical ulcerative and fungating morphology and slow growth of tumor for 4 years. Histopathology and immunohistochemistry are of paramount importance in clinching the diagnosis as was seen in our case. Three histopathological patterns have been described: (1) Trabecular type with connective tissue separating interconnecting cellular trabeculae, (2) Intermediate cell type, which is commonest, with solid nests and trabeculae
MCC is a very aggressive tumor and, hence, the need for early diagnosis and staging. The most frequent sites of metastasis are skin, lymphatics, and liver although potentially any organ including CNS can be affected. PET-CT scans have been widely used in MCC for detecting locoregional nodal and distant metastatic disease and staging work up. It is a noninvasive imaging technique that has the potential to detect occult lesions bigger than 5–8 mm in minimal diameter that are not detectable by other imaging techniques.[10] As PET-CT scanning is a whole-body scan, it helped us in delineating the metastatic metabolically active lesions and lymph nodes, as well as the high metabolic activity of primary lesion suggesting its aggressiveness.

Management of MCC is dependent on tumor staging at presentation, with curative intent for locoregional disease and palliative intent for distant disease. Optimal management of MCC includes surgical excision of primary tumor with wide margins, and adjuvant radiotherapy, chemotherapy, immunotherapy, and molecular-targeted therapy in the case of metastasis.[11] Our patient was managed with wide local excision of the tumor with the histopathological margins being free of tumor and was started on radiotherapy for subcutaneous and intraabdominal metastasis. Patient was offered chemotherapy which he declined, and succumbed to his illness within two months of diagnosis of MCC.

Our case highlights an unusual variant of MCC presenting as an insidious onset ulcerated growth over lower back in an elderly male without any underlying immunosuppression. A high index of suspicion is of paramount importance on the part of the treating dermatologist, for prompt and early diagnosis of MCC to arrest the disease in its incipient stages.

Acknowledgement
Nagendra Singh Beniwal-Department of Dermatology, Military Hospital, Ramgarh, Jharkhand.
Isha Sharma-Department of Pathology, Armed Forces Medical College, Pune.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Cirillo F, Vismarrà M, Cafaro I, Martinotti M. Merkel cell carcinoma: A retrospective study on 48 cases and review of literature. J Oncol 2012;2012:749030.
2. Smith PD, Patterson JW. Merkel cell carcinoma (neuroendocrine carcinoma of the skin). Am J Clin Pathol 2001;115:686-78.
3. Schadendorf D, Lebbé C, Zur Hausen A, Avril M-F, Haritharan S, Bharal M, et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53-69.
4. Gaopande VL, Joshi AR, Khandeparkar SG, Deshmukh SD. Merkel cell carcinoma of the abdominal wall. Indian Dermatol. Online J 2015;6:269-73.
5. Khader A, George S, Balakrishnan S, Aravindan KP. Spontaneous regression in an ulcerated CK7 positive Merkel cell carcinoma. Indian J Dermatol Venereol Leprol 2015;81:170-3.
6. Schrama D, Becker J. Merkel cell carcinoma–pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol 2011;25:1121-9.
7. Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, et al. Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management. J Cancer. 2007;110:1-12.
8. Hanly AJ, Elgart GW, Jorda M, Smith J, Nadji M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000;27:118-20.
9. Becker C, Schrama D. Merkel cell carcinoma. In: Griffith C, Barker J, Bleiker T, editors. Rook’s Textbook of Dermatology. 9th ed. Wiley Blackwell; 2016. p. 145.3.
10. Enzenhofer E, Ulb P, Czerny C, Erovic BM. Imaging in patients with merkel cell carcinoma. J Skin Cancer 2013:2013:973123.
11. Rockville Merkel Cell Carcinoma Group. Merkel cell carcinoma: Recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol 2009;27:4021-6.